Logo

XERS

Xeris Biopharma Holdings, Inc.

XERS

Xeris Biopharma Holdings, Inc. • NASDAQ
$7.18 ▲ 0.00% (+0.00)
Market Cap $1.19 B
52w High $10.08
52w Low $3.14
Dividend Yield 0%
P/E -71.8
Volume 669.45K
Outstanding Shares 165.92M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $74.38M ▲ $56.653M ▲ $621K ▲ 0.835% ▲ $0 ▲ $11.078M ▲
Q2-2025 $71.539M ▲ $52.448M ▼ $-1.928M ▲ -2.695% ▲ $-0.012 ▲ $8.594M ▲
Q1-2025 $60.119M ▲ $54.481M ▲ $-9.22M ▼ -15.336% ▼ $-0.06 ▼ $1.228M ▼
Q4-2024 $60.099M ▲ $48.942M ▼ $-5.113M ▲ -8.508% ▲ $-0.034 ▲ $5.723M ▲
Q3-2024 $54.268M $53.568M $-15.738M -29.001% $-0.11 $-8.152M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $91.598M ▲ $370.191M ▲ $371.052M ▲ $-861K ▲
Q2-2025 $59.285M ▲ $334.686M ▲ $353.99M ▲ $-19.304M ▲
Q1-2025 $58.44M ▼ $315.453M ▼ $350.581M ▼ $-35.128M ▼
Q4-2024 $71.621M ▲ $323.06M ▲ $352.675M ▲ $-29.615M ▼
Q3-2024 $69.402M $321.104M $349.427M $-28.323M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $621K ▲ $18.432M ▲ $-71K ▲ $13.85M ▲ $0 ▼ $18.069M ▲
Q2-2025 $-1.928M ▲ $182K ▲ $-279K ▼ $942K ▲ $845K ▲ $10.044M ▲
Q1-2025 $-9.22M ▼ $-10.031M ▼ $-13K ▼ $-3.137M ▼ $-13.181M ▼ $-10.044M ▼
Q4-2024 $-5.113M ▲ $1.975M ▲ $10.016M ▲ $398K ▲ $12.389M ▲ $1.755M ▲
Q3-2024 $-15.738M $-8.305M $9.914M $-83K $1.526M $-8.392M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Keveyis
Keveyis
 $20.00M ▲$10.00M ▼$10.00M ▲$10.00M ▲
Product
Product
 $100.00M ▲$60.00M ▼$70.00M ▲$70.00M ▲
Product Other
Product Other
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has been climbing steadily from a small base, and the company is clearly in a growth phase rather than a mature one. Gross profit looks healthy relative to sales, which suggests the core products are priced and manufactured reasonably well. However, overall the business is still loss‑making, as operating costs for commercialization, research, and overhead remain higher than gross profit. The encouraging sign is that losses have been shrinking year after year, pointing to improving operating leverage and a gradual move toward potential break‑even if the trend continues.

Balance Sheet

Balance Sheet The balance sheet is relatively small and fairly tight. Total assets have stayed roughly flat, while debt has risen meaningfully over the last few years. Shareholders’ equity has slipped into slightly negative territory, which reflects accumulated losses and a thin capital cushion. Cash on hand has not grown, so there is limited internal buffer against shocks. Overall, the company looks financially stretched, with growing reliance on lenders and a capital structure that leaves less room for prolonged setbacks.

Cash Flow

Cash Flow The business is not yet self‑funding. Operating cash flow has been consistently negative, although the cash burn has been easing over time. Free cash flow tells the same story, with most cash usage coming from running the business rather than from heavy investment in equipment or facilities. The relatively stable cash balance, despite ongoing negative cash flow, implies the company has been supporting itself mainly through external financing. Until operating cash flow turns positive, there remains a dependency on capital markets or partners to fund growth and operations.

Competitive Edge

Competitive Edge Xeris occupies a specialized niche in injectable and rare‑disease treatments, supported by its proprietary XeriSol and XeriJect formulation platforms. These technologies allow more convenient, ready‑to‑use injections that can improve patient and provider experience, which is a real differentiator. The company also has three approved products and an existing commercial infrastructure, which is unusual for a smaller biotech and gives it a head start in marketing and distribution. Strategic partnerships with large pharmaceutical companies further validate its technology and extend its reach. On the other hand, Xeris is still small, relies on a limited number of products and partners, and operates in markets where larger players, changing reimbursement, or new competitors could quickly shift the landscape.

Innovation and R&D

Innovation and R&D Innovation is the clear strength of the company. Its two formulation platforms are protected by intellectual property and can be applied across a range of small molecules and biologics, which creates multiple shots on goal from the same core technology. The existing products, especially in diabetes emergencies and rare endocrine conditions, are concrete proof that the R&D engine can deliver. The pipeline, including a once‑weekly hypothyroidism candidate, targets sizable unmet needs and could significantly expand the business if successful. At the same time, progress depends on clinical trial outcomes, regulatory approvals, and sustained funding, so execution risk and development uncertainty remain high, as is typical in biotech.

Summary

Xeris Biopharma is an early‑commercial‑stage biotech transitioning from a pure R&D story to a revenue‑generating business. The top line is growing and losses are narrowing, indicating improving economics, but the company is still firmly in the investment phase and not yet profitable or cash‑flow positive. Its balance sheet shows rising debt and a thin or slightly negative equity base, which highlights financial risk and continued dependence on external capital. What stands out as the main offsetting strength is a genuinely differentiated technology platform, validated products on the market, and partnerships with major pharmaceutical companies. The long‑term outcome will depend on the company’s ability to keep growing sales of its current products, manage its debt load, and successfully advance its pipeline, all in the face of the usual scientific, regulatory, and competitive uncertainties in the biotech sector.

NEWS

November 6, 2025 · 7:00 AM UTC

Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025

Read more

October 23, 2025 · 7:30 AM UTC

Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025

Read more

October 3, 2025 · 4:15 PM UTC

Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more